Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Werner

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Molecular Oncology|June 6, 2015
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patientsShannon N Westin, Zhenlin Ju, Russell R Broaddus, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|October 28, 2022
Data Set for the Reporting of Endometrial Cancer: Recommendations From the International Collaboration on Cancer Reporting (ICCR)Xavier Matias-Guiu, Christina I Selinger, Lyndal Anderson, et al.
Cancer|March 6, 2026
The impact of the patient macroenvironment on molecular subgroups in endometrial cancerHenrica M J Werner, Frederiek A H van Dijk, Stephanie W Vrede, et al.
Oncotarget|September 17, 2016
Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancerAnna Berg, Kristine E Fasmer, Karen K Mauland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2013
High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibitionElisabeth Wik, Even Birkeland, Jone Trovik, et al.
Scientific Reports|September 2, 2017
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancerSiv Mjos, Henrica M J Werner, Even Birkeland, et al.
The Science of the Total Environment|February 19, 2024
Equipping for risk: Lessons learnt from the UK shale-gas experience on assessing environmental risks for the future geoenergy use of the deep subsurfaceP L Smedley, G Allen, B J Baptie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2018
<i>PIK3CA</i> Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial CarcinomaFrederik Holst, Henrica M J Werner, Siv Mjøs, et al.
Oncotarget|October 6, 2017
Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancersAnna Berg, Ankush Gulati, Sigmund Ytre-Hauge, et al.
Oncotarget|November 22, 2014
Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patientsAnna Berg, Erling A Hoivik, Siv Mjøs, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Molecular Oncology|June 6, 2015
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patientsShannon N Westin, Zhenlin Ju, Russell R Broaddus, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|October 28, 2022
Data Set for the Reporting of Endometrial Cancer: Recommendations From the International Collaboration on Cancer Reporting (ICCR)Xavier Matias-Guiu, Christina I Selinger, Lyndal Anderson, et al.
Cancer|March 6, 2026
The impact of the patient macroenvironment on molecular subgroups in endometrial cancerHenrica M J Werner, Frederiek A H van Dijk, Stephanie W Vrede, et al.
Oncotarget|September 17, 2016
Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancerAnna Berg, Kristine E Fasmer, Karen K Mauland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2013
High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibitionElisabeth Wik, Even Birkeland, Jone Trovik, et al.
Scientific Reports|September 2, 2017
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancerSiv Mjos, Henrica M J Werner, Even Birkeland, et al.
The Science of the Total Environment|February 19, 2024
Equipping for risk: Lessons learnt from the UK shale-gas experience on assessing environmental risks for the future geoenergy use of the deep subsurfaceP L Smedley, G Allen, B J Baptie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2018
<i>PIK3CA</i> Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial CarcinomaFrederik Holst, Henrica M J Werner, Siv Mjøs, et al.
Oncotarget|October 6, 2017
Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancersAnna Berg, Ankush Gulati, Sigmund Ytre-Hauge, et al.
Oncotarget|November 22, 2014
Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patientsAnna Berg, Erling A Hoivik, Siv Mjøs, et al.
Pageof 10